Abstract:

Objective To investigate the efficacy and safety of Nateglinide in the treatment of type 2 diabetes.Methods 50 patients with type 2 diabetes were enrolled and allocated randomly in two groups, the test group (neteglinide group, 25 cases) and the control group (repaglinide group, 25 cases). A clinical study of 12 weeks period was conducted using the random, double-blind, parallel-controlled method.Results Compared with the baseline value(0 week), the HbA₁c, fasting glucose(FBG), 2 h post-meal glucose (2 h PBG) in the test group decreased by 2.45%, 0.82 mmol/L, 3.59 mmol/L respectively in the twelfth week, while the HbA₁c, FBG, 2 h PBG in the control group decreased 3.10%, 1.77 mmol/L, 4.33 mmol/L respectively( P <0.01). There were no significant difference between the two groups in the comparison of the above indexes. During the treatment of 12 weeks, there were no change of clinical significance found in both life signs and laboratory tests.Conclusion Nateglinide can make the HbA₁c, FBG, 2 h PBG significantly decreased and it has an excellent safety and tolerance.

Key words: nateglinide, type 2 diabetes, treat